Baseline amyloid levels predicted amyloid plaque response with donanemab, an investigational drug targeting N-terminal pyroglutamate beta-amyloid in early Alzheimer’s disease, a post hoc review of phase II TRAILBLAZER-ALZ data found.
The rate of donanemab-induced amyloid reduction at 24 weeks was moderately correlated with the amount of baseline amyloid (r −0.54, P
0.001).p>